449 related articles for article (PubMed ID: 18206918)
1. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
2. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Imura M; Oda N; Kiniwa M; Hayashi Y; Kohri K
J Urol; 2011 Oct; 186(4):1530-6. PubMed ID: 21855934
[TBL] [Abstract][Full Text] [Related]
6. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2006 May; 66(7):761-7. PubMed ID: 16425183
[TBL] [Abstract][Full Text] [Related]
7. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
8. [The role of alpha1-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench].
Kojima Y; Hayase M; Imura M; Okada S; Kubota Y; Sasaki S; Hayashi Y; Kohri K
Hinyokika Kiyo; 2008 Jun; 54(6):457-62. PubMed ID: 18634446
[TBL] [Abstract][Full Text] [Related]
9. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
11. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate.
Walden PD; Gerardi C; Lepor H
J Urol; 1999 Feb; 161(2):635-40. PubMed ID: 9915474
[TBL] [Abstract][Full Text] [Related]
12. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
13. History and nomenclature of alpha1-adrenoceptors.
Langer SZ
Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10438241
[TBL] [Abstract][Full Text] [Related]
14. Effect of naftopidil on nocturia after failure of tamsulosin.
Oh-oka H
Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955
[TBL] [Abstract][Full Text] [Related]
15. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
16. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
Ukimura O; Kanazawa M; Fujihara A; Kamoi K; Okihara K; Miki T;
Int J Urol; 2008 Dec; 15(12):1049-54. PubMed ID: 19120513
[TBL] [Abstract][Full Text] [Related]
17. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
[TBL] [Abstract][Full Text] [Related]
19. [The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia].
Ju XB; Wu HF; Su JT
Zhonghua Nan Ke Xue; 2002; 8(4):286-8. PubMed ID: 12491697
[TBL] [Abstract][Full Text] [Related]
20. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
